Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease

Verbraak, F.D.; Boom, W.R.; Wertheim-van Dillen, P.M.E.; van den Horn, G.J.; Kijlstra, A.; de Smet, M.D.

Published in:
British journal of ophthalmology

DOI:
10.1136/bjo.83.10.1186

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease

Frank D Verbraak, René Boom, Pauline M E Wertheim-van Dillen, Gerardus J van den Horn, Aize Kijlstra and Marc D de Smet

*Br. J. Ophthalmol.* 1999;83;1186-1189

Updated information and services can be found at:
[http://bjo.bmj.com/cgi/content/full/83/10/1186](http://bjo.bmj.com/cgi/content/full/83/10/1186)

These include:

**References**
This article cites 13 articles, 5 of which can be accessed free at:
[http://bjo.bmj.com/cgi/content/full/83/10/1186#BIBL](http://bjo.bmj.com/cgi/content/full/83/10/1186#BIBL)

1 online articles that cite this article can be accessed at:
[http://bjo.bmj.com/cgi/content/full/83/10/1186#otherarticles](http://bjo.bmj.com/cgi/content/full/83/10/1186#otherarticles)

**Rapid responses**
You can respond to this article at:
[http://bjo.bmj.com/cgi/eletter-submit/83/10/1186](http://bjo.bmj.com/cgi/eletter-submit/83/10/1186)

**Email alerting service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**
Articles on similar topics can be found in the following collections

- HIV Infection/AIDS (1314 articles)
- Ophthalmology (1579 articles)

**Notes**

To order reprints of this article go to:
[http://www.bmjournals.com/cgi/reprintform](http://www.bmjournals.com/cgi/reprintform)

To subscribe to *British Journal of Ophthalmology* go to:
Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease

Frank D Verbraak, René Boom, Pauline M E Wertheim-van Dillen, Gerardus J van den Horn, Aize Kijlstra, Marc D de Smet

Abstract

Background/aims—In the pre-HAART era, HIV positive patients with CD4+ cell counts below 50 cells ×10⁶/l, and those with detectable cytomegalovirus (CMV) DNA in their peripheral blood, were considered to be at high risk for the development of CMV disease. With the start of highly active antiretroviral therapy (HAART), a restoration of immune function occurred in these patients, and as a consequence patients became less vulnerable to CMV disease. Since it is not exactly known how HAART influences CMV viral load in peripheral blood and the incidence of CMV disease in high risk HIV positive patients a group of patients was followed before and after initiation of HAART.

Methods—29 HIV positive patients, seen in the first 3 months of 1996 at the AIDS clinic of the Academic Medical Centre, at high risk for development of CMV disease (positive CMV DNA assay in blood and/or CD4+ cell count below 50 cells ×10⁶/l), not receiving anti-CMV maintenance therapy, were included in a prospective cohort study. HAART was started in the second trimester of 1996. Patients were evaluated for the occurrence of CMV retinitis, or CMV disease elsewhere, comparing the incidence of CMV events before and after the start of HAART. Following the introduction of HAART, CD4+ cell counts and quantitative polymerase chain reaction (PCR) assays in predicting CMV disease (sensitivity between 75% and 90%; specificity between 60% and 85%; positive predictive value between 60 and 70%; negative predictive value between 80 and 98%). The overall incidence of CMV retinitis in these studies during a follow up period of 12 months was between 25% and 35%. Spector et al reported a 12 month Kaplan–Meier CMV disease event rate of 14% in PCR CMV negative patients and of 43% in the PCR positive patients, corresponding to a 3.4-fold increased risk of developing CMV disease. In over 90% of cases CMV disease manifested itself as retinitis.

The use of antiretroviral combination therapy—for example, triple therapy consisting of two reverse transcriptase inhibitors and one protease inhibitor, often called highly active antiretroviral therapy (HAART), has resulted in a dramatic change in the morbidity associated with HIV. A significant decline in the incidence of CMV disease has been reported in patients receiving this combination antiretroviral therapy. Van den Horn et al reported that patients with CMV retinitis treated with HAART showed no recurrences during a follow up period of 42–52 weeks provided the CD4+ cell counts remained above 100 cells ×10⁶/l. HAART induces a rapid redistribution and eventually a restoration of the immune system, and as a result, patients, normally expected to be at high risk for developing CMV retinitis or recurrences of already...

Conclusion—In HIV positive patients at high risk of CMV retinitis, either with a positive CMV PCR assay in blood and/or with CD4+ cell counts below 50 cells ×10⁶/l, HAART causes a dramatic decrease in the occurrence of CMV disease. This decrease is paralleled by an increase in CD4+ cell count, and a decrease in the amount of CMV DNA in the blood, which was below detection levels in all patients with CD4+ cell counts above 100 cells ×10⁶/l.

Department of Ophthalmology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands
Frank D Verbraak, René Boom, Pauline M E Wertheim-van Dillen

Department of Microbiology, Department of Virology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands
R Boom

Department of Ophthalmic Research Institute, Amsterdam, Netherlands
A Kijlstra

Department of Ophthalmology-Immunology, the Netherlands
M D de Smet

Correspondence to:
Frank D Verbraak, University of Amsterdam, Academic Medical Centre, Department of Ophthalmology, Room G2-245, PO Box 22700, 1100 DE Amsterdam, Netherlands.

Accepted for publication 24 May 1999
Influence of HAART on the development of CMV disease in HIV positive patients

Table 1  Effect of HAART on occurrence of CMV events and survival in HIV positive patients at high risk for developing CMV disease

<table>
<thead>
<tr>
<th></th>
<th>Before HAART (n=29)</th>
<th>After HAART (n=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV events (n)</td>
<td>PCR+ (n=20)</td>
<td>PCR− (n=9)</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>0.5, 2, 2, 3</td>
</tr>
<tr>
<td>Death (n)</td>
<td>3</td>
<td>1, 2, 2, 4</td>
</tr>
<tr>
<td>Living, without anti-CMV maintenance therapy (n)</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Mean follow up (months)</td>
<td>5.0†</td>
<td>14.9‡</td>
</tr>
</tbody>
</table>

HAART = highly active antiretroviral therapy; PCR = polymerase chain reaction; + = positive result, − = negative result; *time between start of study and occurrence of event/death; †mean follow up between start of study and start of HAART; ‡mean follow up following start of HAART.

Patients and methods

PATIENT SELECTION

Patients were selected from a group of 100 consecutive HIV positive patients seen in March and April 1996 at the AIDS clinic of the Academic Medical Center of the University of Amsterdam. Eligible patients either tested positive for CMV PCR in blood (n=18), or had a CD4+ count below 50 cells ×10⁶/l (n=15). With two exceptions all PCR positive patients had a CD4+ count below 50 cells ×10⁶/l. Four patients refused to participate. All other patients (n=29) underwent a full ophthalmological examination, including fundoscopy in mydriasis at baseline.

A CMV event could be either a CMV retinitis, defined as a necrotising retinitis with characteristic “cheese-like” appearance with or without haemorrhages, as observed by an experienced ophthalmologist, or extracocular CMV disease, for which diagnosis immunohistochemical proof had to be present.

Before the start of HAART four patients died without clinically manifest CMV disease, after 4, 7, 9, and 15 weeks respectively. The mean follow up period for the other patients from the start of the study to the start of HAART was 5 months (range 4–6 months). All patients were given HAART in the second trimester of 1996. HAART consisted of triple therapy, using a combination of two reverse transcriptase inhibitors and one protease inhibitor.

Three patients developed CMV retinitis and received anti-CMV maintenance therapy. These patients were excluded from further follow up. Mean follow up after the start of HAART for those patients not receiving anti-CMV maintenance therapy (n= 22), was 14.9 months (range 8–22 months).

Between November 1996 and July 1998 the 22 patients without anti-CMV maintenance therapy underwent a full ophthalmological examination, including fundoscopy in mydriasis, every month during the first 6 months, and every other month during the remaining part of follow up. At the same time blood samples were taken for quantitative PCR analysis. At each visit patients were asked for complaints related to oesophagitis, colitis, pneumonia, or neuropathy. Additionally at each visit, the treating physician from the department of internal medicine received a questionnaire and was explicitly asked for any signs of extracocular CMV disease. CD4+ cell counts were performed every third month.

PCR ANALYSIS

CMV DNA was purified from 50 µl EDTA blood specimens together with 70 molecules of internal control (IC) DNA as described previously, using 20 µl of size fractionated silica particles. DNA was eluted in 100 µl TE buffer (10 mM TRIS, 1 mM EDTA, pH 8.0). CMV DNA levels in blood were determined by real-time PCR described previously (Boom R, Sol C, Weel J, et al. A highly sensitive assay for detection and quantification of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence, submitted). In short, purified DNA (25 µl) was subjected to a 35 cycle PCR with a single primer pair which amplifies a 578 bp DNA fragment from exon 4 of the major immediate early gene of CMV and a fragment of identical size and GC content from IC DNA. The amounts of CMV and IC PCR products were subsequently determined by electrochemiluminescence (ECL) in the QPCR System 5000 (Perkin Elmer) after hybridisation with (TRIS (2,2’-bipyridine) ruthenium (II) chelate) (TBR) labelled probes specific for either CMV or IC amplimers. The viral load (expressed as copies CMV/ml blood) was calculated from the ratio (R) of CMV over IC ECL signals (after background correction) by the algorithm “copies CMV/ml blood = R × 1400”.

STATISTICAL ANALYSIS

For statistical analysis we compared the CMV event rate, during follow up before the start of HAART, with CMV event rate following the start of HAART, using the Kaplan–Meier method and the log rank test.

Results

Four patients, all belonging to the CMV PCR positive patient group, developed a clinically manifest CMV disease in the pre-HAART period, after 1, 7, 9, and 12 weeks. Three patients were diagnosed with a CMV retinitis and all were put on maintenance therapy after successful induction therapy. One patient developed a CMV colitis and only received a 3 week induction therapy. Additionally, four patients died before the start of HAART; without clinically manifest CMV disease, after 4, 7, 8, and 17 weeks respectively (Table 1).
Table 2: Effect of HAART on CD4+ cell counts and CMV viral load in 22 HIV positive patients, without anti-CMV maintenance therapy, at high risk for developing CMV disease

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Before HAART</th>
<th>After HAART</th>
<th>Last exam</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD4+</td>
<td>PCR</td>
<td>CD4+</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
<td>1469</td>
<td>70</td>
</tr>
<tr>
<td>2</td>
<td>150</td>
<td>914</td>
<td>150</td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>1136</td>
<td>210</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>562</td>
<td>90</td>
</tr>
<tr>
<td>5</td>
<td>40</td>
<td>1529</td>
<td>160</td>
</tr>
<tr>
<td>6</td>
<td>40</td>
<td>382</td>
<td>30</td>
</tr>
<tr>
<td>7</td>
<td>40</td>
<td>2355</td>
<td>100</td>
</tr>
<tr>
<td>8</td>
<td>90</td>
<td>1259</td>
<td>170</td>
</tr>
<tr>
<td>9*</td>
<td>30</td>
<td>1423</td>
<td>90</td>
</tr>
<tr>
<td>10*</td>
<td>20</td>
<td>604</td>
<td>140</td>
</tr>
<tr>
<td>11</td>
<td>30</td>
<td>10</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>20</td>
<td>60</td>
<td>6488</td>
</tr>
<tr>
<td>13</td>
<td>20</td>
<td>30</td>
<td>186</td>
</tr>
<tr>
<td>14</td>
<td>10</td>
<td>110</td>
<td>—</td>
</tr>
<tr>
<td>15</td>
<td>20</td>
<td>60</td>
<td>90</td>
</tr>
<tr>
<td>16</td>
<td>50</td>
<td>20</td>
<td>190</td>
</tr>
<tr>
<td>17</td>
<td>30</td>
<td>70</td>
<td>—</td>
</tr>
<tr>
<td>18</td>
<td>10</td>
<td>230</td>
<td>—</td>
</tr>
<tr>
<td>19</td>
<td>10</td>
<td>80</td>
<td>—</td>
</tr>
<tr>
<td>20</td>
<td>30</td>
<td>140</td>
<td>ND</td>
</tr>
<tr>
<td>21</td>
<td>30</td>
<td>50</td>
<td>80</td>
</tr>
<tr>
<td>22*</td>
<td>30</td>
<td>120</td>
<td>—</td>
</tr>
</tbody>
</table>

CD4+ = CD4+ cell count (×10⁶/l); HAART = highly active antiretroviral therapy; PCR = quantitative polymerase chain reaction, in copies CMV ×10⁶/ml; — = negative result; ND = not done; exam 0 = first examination, at intake, before the start of HAART; exam 1–7 = examinations, monthly, after the start of HAART. After the 7th examination, follow up scheduled every other month, results not shown. *Patient 9, 10, and 22 previous diagnosis of extraocular CMV disease; †patient 7 one negative result; ND = not done; exam 0 = first examination, at intake, before the start of HAART; exam 1–7 = examinations, monthly, after the start of HAART. After the 7th examination, follow up scheduled every other month, results not shown. 

Discussion
In this study we present data showing that in 22 patients, previously considered to be at extremely high risk for developing CMV disease, not one new case of CMV disease manifested itself during a mean follow up of 14.9 months (range 8–22 months).

HAART resulted in a gradual rise in CD4+ lymphocyte counts and a gradual drop in CMV viral load in the peripheral blood. At the last examination CMV DNA became undetectable, with the exception of one patient whose CD4+ cell count remained less than 100 cells ×10⁶/l. No patient died during follow up.

Comparing the incidence of CMV disease in the patients before and after the start of HAART, using the Kaplan–Meier method with the log rank test, we found a statistically significant, albeit weak, difference between both observation periods (p = 0.05). A placebo controlled trial (withholding HAART to these patients) was considered to be unethical.

Patients with a history of extraocular CMV disease have been reported to be especially prone to the subsequent development of CMV retinitis. Over 85% of these patients developed a CMV retinitis after a mean follow up of 6.4 months. The fact that no clinically manifest CMV disease occurred in our group of HIV positive patients can only be explained by the success of the HAART treatment. Others have also reported the decreased incidence of CMV disease in HIV positive patients with favourable responses to HAART treatment. The decrease of CMV viral load found in this study confirms the restoration of the immune system,
Influence of HAART on the development of CMV disease in HIV positive patients

1189

retinitis. This was believed to be due to reactivation from their latent CMV infection. All four patients with clinically manifest CMV disease in the pre-HAART period belonged to the group of patients with a CMV PCR positive blood test. This observation confirms the predictive value of the PCR assay, even though the patient number is small, and pre-HAART follow up short (sensitivity 100%, specificity 55%, positive predictive value 23%, negative predictive value 100%). The test results compare favourably with those reported in the literature, suggesting at least an equal sensitivity.

Although HAART is considered very effective in treating HIV infection, with a sometimes dramatic improvement in the clinical manifestations of opportunistic infections, CMV disease has been reported in HIV positive patients after the start of HAART, even after a rise of CD4+ lymphocyte count above 100 cells \(\times 10^6/l\). Diagnosis was made very shortly after the initiation of HAART, within a 4–8 week period. During the rest of follow up after these first 2 months, not one new case of CMV disease occurred in these studies.

After the start of HAART, uveitis or vitritis has been described in some patients with CMV retinitis. This was believed to be due to restoration of the previously deficient immune response in these patients, leading to an intracellular inflammatory response against the virus. In our study no new case of CMV retinitis developed after the start of HAART, nor did any patient showed signs of uveitis.

We conclude that in HIV positive patients at high risk for development of CMV disease, either with a positive CMV PCR assay in blood and/or with CD4+ lymphocyte counts below 50 cells \(\times 10^6/l\), HAART causes a dramatic decrease in the occurrence of CMV disease. This decrease is paralleled by an increase in CD4+ lymphocyte count, and a decrease in the amount of CMV DNA in the blood, which becomes undetectable in all patients with CD4+ cell counts above 100 cells \(\times 10^6/l\).